|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Dvořákovo nábrežie 10, Bratislava, SK
|
|
AXON Neuroscience is a clinical-stage biotech company founded in 1999 with a specialized team of researchers focused exclusively on tau immunotherapies and tau diagnostic platforms. AXON has identified and wholly owns several compounds which are being investigated as potentially disease-modifying therapies for the treatment of Alzheimer's disease and other tauopathies. The two lead compounds are the active vaccine AADvac1 and the monoclonal antibody AADvac2. The tau vaccine AADvac1 has potential to be the first breakthrough therapy to address Alzheimer's disease and help millions of people suffering from the devastating disease. Axon is also developing a suite of diagnostic assays to more accurately identify patients with potential tau-derived brain diseases that can benefit from its novel therapeutic candidates.
|
AXON Neuroscience Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used AXON Neuroscience email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact AXON Neuroscience customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.